Applied Genetic Technologies Corporation
ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF GENETIC HEARING LOSS

Last updated:

Abstract:

Described herein are optimally-modified GJB2 cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for the treatment of genetic hearing loss.

Status:
Application
Type:

Utility

Filling date:

30 Sep 2020

Issue date:

1 Apr 2021